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Introduction
Homeostasis of the central nervous system (CNS) microenvironment is essential for its normal function and is maintained by the blood-brain barrier (BBB) (Pardridge, 1988; Risau & Wolburg, 1990) . The cell types composing the BBB are endothelial cells, pericytes and the end-feet of astrocytes. Among them, several recent studies have highlighted the importance of the brain endothelial cells to form the morphological correlative of the BBB in this modular organization: the permeability properties of the BBB reflect, to a major degree, the tightness of the intercellular junctions between brain microvascular endothelial cells (Rubin et al., 1991) . Tight junctions (TJ) seal the endothelial cell layer and are especially well developed in endothelia of the BBB, in contrast to blood vessels outside the CNS, the TJs of which are less elaborate and facilitate exchange of solutes and macromolecules and allow leukocyte trafficking (Simionescu & Simionescu, 1991) . Two different classes of integral membrane proteins constitute the TJ strands, occludin and members of the claudin protein family (D'Atri & Citi, 2002) . The claudins, which have been identified in brain microvascular endothelial cells include claudin-5, claudin-12 (Matter & Balda, 2003) , claudin-1 (Liebner et al., 2000) and claudin-3 (Wolburg et al., 2003; Coisne et al., 2005) . Moreover, numerous studies have demonstrated conclusively that TJ formation depends very much on the VE-cadherin-based adherens junctions (Lampugnani et al., 1995; Gumbiner, 1996) .
Disruption of the blood-brain barrier (BBB) has been described as a crucial step of neuroinflammatory conditions including brain tumors, cerebral ischemia, meningitis, encephalitis, and multiple sclerosis (MS). Therapeutic strategies for several of these diseases include treatment with GC (Engelhardt, 2000; Qizilbash et al., 2002 ) but a detailed understanding of their mechanism of action is still outstanding. GCs exert a 5 variety of beneficial effects under neuroinflammatory conditions by acting on immune cells, the microglia and the blood-brain barrier, but they do fail to improve cerebral edema following stroke or even show adverse effects like the induction of hypertension in chronical administration, so that there is a clear need to further elucidate their molecular mode of actions (Reichardt et al., 2006) . Effects of GCs like hydrocortisone (HC) are known to be mediated by the glucocorticoid receptor (GR) (Beato, 1989) . GR can bind to specific DNA sequences (glucocorticoid-responsive element, GRE) in the 5'-flanking region of target genes and transactivate gene transcription (Beato, 1989) . Despite great progress in the field, many questions concerning the mechanism of GCs remain unanswered, for example the contribution of genomic and non-genomic effects or the cell-type specificity of their action.
Barrier-tightening effects of GC treatment has been demonstrated for cerebral endothelial cells in vitro (Hoheisel et al., 1998; Romero et al., 2003; Förster et al., 2005; Weksler et al., 2005) . Matching data supporting an important role for GCmediated tightening of the BBB by junctional protein induction have been demonstrated in vivo in the mouse . GCs have further been shown to effectively restore barrier in a rat model of MS (Paul & Bolton, 1995; Schmidt et al., 2003) . Moreover, using serial MRI recordings, a reduction in the number of enhancing lesions has been observed in patients suffering from optic neuritis and MS after high-dose GC treatment and in clinical studies (Grauer et al., 2001 ).
Based on these effects, researchers have begun to use diverse GCs for the in vitrodifferentiation of in vitro models of the BBB (Hoheisel et al., 1998; Romero et al., 6 2003; Förster et al., 2005; Weksler et al., 2005) . In vitro BBB models are isolated endothelial cell culture systems from brain capillaries that allow for the study of BBB functionality, e.g. GC action, separated from feedback or indirect systems that operate in vivo. Several in vitro BBB systems have been developed and various procedures have been applied to isolate and culture brain microvascular endothelial cells. They differ with respect to e.g. isolation procedure, culture conditions, cell type and origin (tissue and species) and culture system. Such a diversity leads to in vitro BBB systems with different characteristics, which makes the comparison and transference of results between these systems problematic.
For the transference of results to therapy, it is a necessary step to characterize human brain endothelial cell features in response to GCs versus those from animal origin and to delineate the molecular targets of GC action also in the human system. There was no established immortalized human brain endothelial cell line so far that could be used as an adequate in vitro-model to investigate the effects of GCs on the differentiation and regulation of the blood brain barrier in humans. Due to this shortcoming, a transference of molecular mechanisms induced by GC administration in animal models to the human system has not yet been achieved. After establishing hCMEC/D3 as an immortalized validated human model of the blood brain barrier (Weksler et al., 2005; Cucullo et al., 2007) we can now focus onto analysing molecular mechanisms of GC action at the human blood brain barrier. In the present study, the in vitro expression of the GR and the cellular response to the proinflammatory cytokine TNFα and the GC HC was examined in hCMEC/D3 cells.
Data are then compared to established GC-responsive brain endothelial cell lines from murine, rat or porcine origin characterised previously, and qualitative and quantitative differences are discussed. The future use of the cell culture model hCMEC/D3 might 7 7 help to understand and hopefully even treat neurological disease in a more effective way.
Methods
Chemicals. Hydrocortisone was purchased from Sigma, Taufkirchen, Germany.
Collagen IV was purchased from Fluka, Taufkirchen, Germany.
Isolation and culture of cerebral endothelial cells. The immortalised human brain microvascular endothelial cell line hCMEC was generated as described (Weksler et al., 2005) . The human brain microvessel endothelial cell line hCMEC/D3 retains the morphological characteristics of primary brain endothelial cells and expresses specific brain endothelial markers and cell surface adhesion molecules (Weksler et al., 2005) .
Moreover, it was recently demonstrated that, when cultured under flow conditions, these cells maintain in vitro the physiological permeability barrier properties of the BBB in situ even in the absence of abluminal astrocytes (Cucullo et al., 2007): hCMEC/D3 cells do retain the expression of endothelial and BBB markers (Weksler et al., 2005) , hCMEC/D3 cells retain an aerobic metabolic pathway and exhibit an inflammatory response, i.e. barrier failure, extravasation of leukocytes of these cells (Cucullo et al., 2007) .
Cell Cultures. hCMEC/D3 were cultivated as described by Weksler et al (Weksler et al., 2005) with modifications: until confluence, cells were grown on collagen IVcoated flasks in EGM-2 medium from Clonetics (Cambrex BioScience, Workingham, UK) consisting of EBM-2 basal medium amended with 2.5 % FCS and the growth factors VEGF, IGF-1, EGF, basic FGF, heparin as well as ascorbate and gentamycin from the EGM-2 BulletKit according to the manufacturers recommendation as 9 previously described (Weksler et al., 2005) . Briefly, for EGM-2 preparation, 500 µl bFBF single aliquots and 125 µl of each, IGF1, ascorbic acid, VEGF, EGF, Heparin single aliquots were added to 500 ml EBM-2 basal medium as described in the manufacturers recommendation. As important modification to this protocol, no HC supplementation from the EGM-2 bullet kit was added to the growth medium. After reaching confluence, the medium was changed to a serum-reduced but hormonesupplemented cell differentiation medium: consisting of EBM-2 basal medium containing 0.25 % FCS and 100 nM HC, but without other added growth factors described for the growth medium.
All cultures were supplemented with 100 IU/ml penicillin and 100 mg/ml streptomycin (1% PEST). Cells were maintained in an atmosphere of 5.0% CO 2 / 95 % air and at 37 °C.
Electrophoresis and immunoblotting.
Cells were plated at a density of 2.5*10 4 cells/cm 2 in collagen IV-coated (Fluka, Taufkirchen, Germany) petri dishes and grown to confluence. At confluence, cells were maintained in FCS-reduced differentiation medium (see above) and treated with TNFα and HCs as indicated in the figure legends.
For western blot analyses, cells were then dissolved in Laemmli sample buffer (Laemmli, 1970) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, 15 % gels).
Protein contents were quantified by protein estimation directly from SDS-PAGE loading buffer using 0.1 % (w/v) Amidoschwarz (AppliChem, Darmstadt, Germany) 
Quantitative real-time RT-PCR
For real-time RT-PCR, cDNA was synthesized using iSCRIPT cDNA synthesis kit Throughout, averaged values were reported as means + standard error (SE). The indicated statistical test (Mann-Whitney U-test) was performed assuming significance for P < 0.05 (*), high statistical significance at p < 0.001 (**).
Results

HC responsivity of hCMEC/D3 cells
In an effort to investigate HC-sensitivity of hCMEC/D3 cells we examined GC
receptor ( Summarising protein expression data collected by western blot analysis and immunocytochemistry, we show that ligand-bound GR is translocated to the nucleus in human BBB endothelial cells hCMEC/D3 as reported for classical GC-responsive cells (Beato & Klug, 2000) .
Effects of HC on brain EC resistance and permeabililty
We were able to develop a serum-reduced but hormone-supplemented cell differentiation medium based on the media previously described for murine cEND brain microvascular endothelial cells (Förster et al., 2005) and hCMEC/D3 cells (Weksler et al., 2005) : until confluence, cells were grown in EGM-2 medium from Clonetics (Cambrex BioScience, Workingham, UK) in the presence of 2.5 % FCS and the growth factors VEGF, IGF-1, EGF, basic FGF, heparin as well as ascorbate and gentamycin from the EGM-2 BulletKit as previously described (Weksler et al., 2005) but without HC supplementation used in this reference. The amounts of growth factor single aliquots used for this study are detailed in the method section. After reaching confluency, the medium was changed to the following serum-reduced but hormonesupplemented cell differentiation medium: medium contained 0.25 % FCS and 100 nM HC, but was lacking other added growth factors.
HC supplementation of the serum-reduced cell differentiation medium led to a significant increase in TER across the hCMEC/D3 monolayer. TER in the absence of HC was 69 + 19.3 Ω x cm 2 while HC administration caused a significant increase of TER to the range of 199 + 5 Ω x cm 2 ( Fig. 2A) .
To further validate the hCMEC/D3 BBB model, the paracellular permeability of macromolecules like non-charged FITC-dextrans of molecular masses 4 kDa, 10 kDa, 70 kDa, and 150 kDa and of fluorescein (Mr = 300 Da) was tested by assessing flux across the hCMEC/D3 monolayer after removal of unconjugated FITC from the uptake mix by size exclusion chromatography as previously described (Romero et al., 2003; Förster et al., 2005) (Table 1) . For this, we determined the permeability coefficients using the slopes of the curves representing cleared volume versus time according to van Bree (van Bree et al., 1988) . The permeability of small macromolecules across the monolayer of hCMEC/D3 cells in differentiation medium (0.25 % FCS) supplemented with 100 nM HC was significantly decreased over 90 min for fluorescein (by 48 + 6 %) and the for the smallest FITC-dextran (4-kDa) (by 37 + 4%) comparative to control cells maintained in HC-free medium containing 0.25 % FCS (n = 6-8 filters, 3 independent assays). No significant decrease versus untreated cells was observed for the FITC-dextrans 10-kDa, 70-kDa and 150-kDa (Table 1) . According to the classical pore theory (van Bree et al., 1988) , one can relate the molecullar radius of the solutes assessed (R) with their free diffusion coefficients (D) and the permeability coefficient Pe (Table 1 ). The calculation of the apparent pore size of the paracellular pathway revealed the existence of cylindrical pores of two apparent sizes, a large pore population with a radius of 92 + 9 Å and a small pore population with a radius of 12.47 + 0.45 Å within the hCMEC/D3 monolayer. Hydrocortisone treatment reduced the apparent pore size of the small pores to a radius of 7.9 + 0.3 Å consistent with the reduced permeability of the monolayers following HC treatment. The calculation of the fractional porous area/ path length as through the cell monolayer, i.e. Ap/dx, was calculated as a measure of steric hindrance through the pores in the D3 monolayer (Table 1) . Results show that steric hindrance appears to be significantly reduced by hydrocortisone treatment for all the molecules tested as compared to untreated cells.
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The presented data underline that HC-induced enhanced resistance to electrical current appears to be mainly caused by closure of small-sized pores, responsible for the passage of fluorescein and the smallest of the dextrans tested (4 kDa), but that other effects independent of the tight junction molecules seem to be additionally induced by HC treatment. Taken Claudin-5 contents were increased by 62 + 22 % as compared to the untreated control, as assessed by western blot analysis and and densitometric quantitation. Occludin contents were increased by 16 + 7 % as compared to the untreated control. No effects were detected in the case of claudin-1 and VE-cadherin (Fig. 3) .
Also by real time-RT-PCR analysis we could show that treatment with HC influenced gene expression of junctional protein encoding genes differently in a concentrationdependent manner (Table 2) . As described previously for murine brain microvascular endothelial cells (Förster et al., 2005; Förster et al., 2006) , 1995; Korner & Sedgwick, 1996; Pan et al., 1996) . In order to identify functional changes in the brain endothelium, we assessed TER and barrier constituting junctional protein and mRNA levels in response to treatment with the pro-inflammatory cytokine TNFα and a combination of TNFα and HC treatment (Fig. 4 , (Fig. 4A) .
In order to identify potential mechanisms of HC preservation of the blood brain barrier under pro-inflammatory conditions we assessed changes in junctional protein levels and gene expression (Fig. 4B, Table 3 ). A significant reduction in levels of the TJ proteins occludin and claudin-5 was observed by Western Blot and densitometric quantitation (Fig. 4B,C (Fig. 4B) . We also assessed whether the inflammatory cytokine or the HC would influence levels of the adherens junction protein VE-cadherin could however not detect significant changes under most treatments. Surprisingly, only HC treatment concomitant with TNFα-treatment led to an increase in detectable VE-cadherin protein (118 + 5 % of control) 8 h after treatment (Fig. 4B,C) .
Also by real time-RT-PCR analysis we could show that treatment with the inflammatory mediator TNFα alone or simultaneous treatment with HC influenced gene expression of junctional components differently (Table 3).
All the endothelial cells studied expressed occludin. Occludin mRNA levels were not reduced in response to 8 hours TNFα treatment. Co-treatment with TNFα/ HC maintained occludin gene expression at the control level. As described previously (Förster et al., 2005; Förster et al., 2006) , treatment with HC alone even stronger induced occludin gene expression. In contrast, the expression of claudin-5 and VE- The situation differed from observations in the case of VE-cadherin: a downregulation of gene expression in response to TNFα was equally observed and could be prevented with simultaneous HC treatment while treatment with the GC HC alone did not significantly increase gene expression levels (Table 3 ).
The influence of TNFα on hCMEC/D3 cells was observed from 0.5 till 24 hours after the beginning of the treatment. We observed most pronounced differences in gene expression after a period of eight hours, a longer treatment did not lead to any differences.
Discussion:
Breakdown of the BBB is a key feature of neuroinflammatory conditions, such as MS, encephalitis, meningitis, brain tumors and cerebral ischemia (Hamann et al., 1995; Rosenberg, 2002; Sellner & Leib, 2006) . Therapeutic strategies for such diseases with impaired BBB function include treatment with GCs (Engelhardt, 2000) although the mechanism of GC action is still not precisely determined. Barrier tightening effects of GC treatment have so far been demonstrated in clinical studies (Grauer et al., 2001) , in vivo in animal models (Paul & Bolton, 1995; Schmidt et al., 2003; Förster et al., 2006) , and in isolated cerebral endothelial cells from murine (Förster et al., 2005) or rat (Romero et al., 2003) origin identifying molecular targets for GC action at the cellular level. The verification of identified molecular GC targets in human cells has
however not yet been achieved although necessary in order to apply results from diverse animal models to man and to further prospective therapeutic exploitation.
For the characterisation of hCMEC/D3 GC responsivity, we considered it appropriate to initially examine GR receptor status and barrier induction in this cell line. Our results indicated that human hCMEC/D3 cells express the GR. Our data further showed that GR message and protein in the presence of ligand is reduced in a concentration dependent manner. Remaining GR protein is translocated from the cytosol to the nucleus in hCMEC/D3 cells, as described for classical GC-responsive cells (Beato, 1989) . Hormone-dependent down-regulation of steroid receptors, i.e. GR and the related progesterone receptor (PR), has been demonstrated in the past (Beato & Klug, 2000; Lange et al., 2000) and might be necessary for the attenuation of transcriptional responses in tissues continually exposed to ligand (Shen et al., 2001 ), a situation occuring precisely in the blood vessel-lining endothelial cells.
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The GC HC was found to significantly induce barrier properties in the hCMEC/D3 BBB model. The maximal effect of HC was reached at a concentration of 100 nM or above, which is well in the physiological concentration range of HC in mammalian blood between 70 -550 nM (Karlson et al., 1994) . hydrocortisone on the endothelial glycocalyx, the diminution of which increases capillary permeability, suggesting that the glycocalyx contributes to endothelial 24 permeability barrier formation and is yet another target for hydrocortisone action (Chappell et al., 2007) . Effects on the endothelial glycocalyx of D3 monolayers might thus have occured independently of effects on tight junction molecules.
Future investigation will thus have to clarify the degree of pore size reduction and a possible reduction in pore number by HC treatment and have moreover to address so far unacknowledged effects on the endothelial glycocalyx.
Comparable effects on barrier tightness have been previously reported under HC treatment for the murine brain microvascular endothelial cell line cEND (Förster et al., 2005; Förster et al., 2006) , primary porcine BCECs (Hoheisel et al., 1998) , rat brain microvascular endothelial cells (Romero et al., 2003) and for cells of epithelial origin (Nguyen & Neville, 1998; Woo et al., 2000) . The data are further concordant with clinical reports describing the barrier closing effects of GCs on MRI gadolinium enhancement in acute demyelinating lesions (Burnham et al., 1991) or in optical nerve neuritis (Grauer et al., 2001) .
In an attempt to elucidate the molecular targets of GC-induced tightening of the barrier, we were able to show that GC signals can directly act at the transcriptional level on human occludin and claudin-5 gene expression in a dose-dependent manner.
This induction of gene expression was further reflected in increased occludin and claudin-5 protein synthesis, identifying them as molecular targets of GC action in human brain microvascular endothelial cells. Levels of another TJ protein, claudin-1, and the adherens junction protein, VE-cadherin remained unchanged by GC treatment.
These data are partly consistent and partly disparate from observations in animal models of the BBB, pointing to inter-species differences in GC responsivity: in the mouse BBB model cEND, occludin could similarly be identified as a GR target (Förster et al., 2005) , while an effect on claudin-5 gene expression by GCs was not observed (Förster et al., 2007) . Induction of claudin-5 protein by GCs has however previously been described in other species than mouse: in rat brain microvessel endothelial cells (BMEC, GPNT), addition of HC to the cultures resulted in fewer frayed junctions and a more uniform distribution of the TJ protein claudin-5 at the cell borders as compared with cultures without GC treatment (Romero et al., 2003; Calabria et al., 2006) . A recent screen of gene expression by human alveolar epithelial cells indicated that claudin-5 is one of the major genes upregulated during differentiation in culture (Gonzales et al., 2002; Daugherty et al., 2004) . On the other hand, responsivity of the human VE-cadherin gene to GCs could not be observed in hCMEC/D3 cells, while it represents a GC target in the mouse (Blecharz et al., 2007) .
Reports on GC effects on VE-cadherin in other species or tissues could not be found, while the epithelial adherens protein, E-cadherin was reported to be strongly induced by GC in human lung epithelial cell lines promoting the formation of an alveolocapillary barrier in vitro (Hermanns et al., 2004) . In contrast to this, GCs did not modulate the production or location of the epithelial cell adhesion protein E-cadherin in mouse mammary epithelial cells in vitro (Zettl et al., 1992) . Whether this differential responsivity of the human, rat and mouse claudin-5 and VE-cadherin genes to GCs is based on different temporal gene expression patterns, the diverse GCs used or on different inter-species responsivity of the respective gene promoters to GCs remains to be investigated in the future. The discrepancy observed is however a strong indication to treat the transferability of results obtained in animal models to the human system with caution.
The contribution of individual TJ proteins on the development or progression of neurological conditions is varied. In some cases, TJ alterations and subsequent increased BBB permeability are an effect of the underlying pathology; alternatively, these changes can be causative and mediating event in disease development. For example, TJ disruptions and subsequent BBB perturbations are involved in the development of MS (Neuwelt, 2004; Brooks et al., 2006) , while ischemic stroke and traumatic brain injury lead to BBB perturbations (Ilzecka, 1996) . There are many diseases, such as Alzheimer's disease, where the direct correlation is not yet known, but is currently being investigated (Wardlaw et al., 2003) . We thus attempted further to validate the hCMEC/D3 cell culture model suitable to study the barrier-preserving effects of HC under inflammatory conditions, and were able to demonstrate that TNFα treatment leads to divergent down-regulation of the different TJ proteins.
However, our study demonstrates that the simultaneous administration of HC with
TNFα preserves the functional integrity of the TJs under inflammatory conditions (TNFα  exposure). The selective down-regulation of the TJ proteins occludin and claudin-5 detected is congruent with other research and clinical reports concerning endothelial cells of the BBB (Brooks et al., 2005; Förster et al., 2005; Brooks et al., 2006; Silwedel & Förster, 2006; Schreibelt et al., 2007) and non-neural endothelium (Zeissig et al., 2007) . Pre-treatment with HC maintained the TJ component occludin while it did not prevent the loss of claudin-5 and VE-cadherin as effectively. The observed effects suggest a vulnerability especially of claudin-5 protein to the proinflammatory cytokine. While the TJ transmembrane protein occludin seems to play a regulatory role in the control of vascular permeability, since tissue expression and content of occludin correlate well with barrier properties (Hirase et al., 1997) , the role of the different claudins appears to be strand and pore formation (Matter & Balda, 2003) . (Koto et al., 2007) , while in a rat rat cortical cold injury model, Nag et al. were able to demonstrate decreased expression of both, occludin and claudin-5 at the site of injury (Nag et al., 2007) .
TNFα and HC thus seem to act in a differential manner on the expression of different TJ components in microvascular cells of the BBB. Attention should however also be directed to the possibility that exposure to high levels of the proinflammatory cytokine TNFα can lead to increased amounts of locally produced VEGF from the endothelial cells, which will contribute to the downregulation of TJ proteins and increase leakiness of the barrier. HC effects could therefore also be indirect in nature by reducing VEGF secretion (Neuwelt, 2004) . Future studies will thus have to adress the nature of the opposed effects of HC and TNFα  or other pro-inflammatory cytokines on TJ properties in brain microvascular endothelial cells, i.e. effects on TJ transcription, protein synthesis, intracellular localisation, phosphorylation status, on the dynamics of junctional protein interactions, and on the secretion of signalling proteins and peptidases, in line with investigations in other cellular systems (Poritz et al., 2004; Bruewer et al., 2005; Prasad et al., 2005; Abbott et al., 2006; Förster et al., 2007) .
Taken together, our observations support the hypothesis that the secretion of proinflammatory cytokines during inflammation in endothelial cells leads to the degradation of chiefly claudin-5 and, to a minor extent, occludin, at the human BBB and could affect TJ structural integrity, while HC treatment is an effective way to prevent this. To the best of our knowledge, this is the first report describing a possible 
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The slides were analysed using a Zeiss Axioscop2 microscope. All pictures within each experiment were captured and manipulated identically with SpotAdvanced software and Adobe Photoshop. Bar in the lower panels indicates 20 µm for all panels. and VE-cadherin (Fig. 3) . increased to 110 + 1.5 % of control (Fig. 4B) . Levels of the adherens junction protein VE-cadherin did not show significant changes under most treatment regimes.
However, HC treatment concomitant with TNFa-treatment led to an increase in detectable VE-cadherin protein (118 + 5 % of control) 8 h after treatment.
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